company background image
RZLT

Rezolute NasdaqCM:RZLT Stock Report

Last Price

US$2.77

Market Cap

US$102.0m

7D

7.8%

1Y

-38.9%

Updated

07 Feb, 2023

Data

Company Financials +

RZLT Stock Overview

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States.

RZLT fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Rezolute, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Rezolute
Historical stock prices
Current Share PriceUS$2.77
52 Week HighUS$5.01
52 Week LowUS$1.34
Beta2.3
1 Month Change54.75%
3 Month Change65.87%
1 Year Change-38.85%
3 Year Change-52.65%
5 Year Change-92.09%
Change since IPO-99.58%

Recent News & Updates

We Think Rezolute (NASDAQ:RZLT) Can Afford To Drive Business Growth

Jan 31
We Think Rezolute (NASDAQ:RZLT) Can Afford To Drive Business Growth

Rezolute GAAP EPS of -$0.37

Sep 15

Recent updates

We Think Rezolute (NASDAQ:RZLT) Can Afford To Drive Business Growth

Jan 31
We Think Rezolute (NASDAQ:RZLT) Can Afford To Drive Business Growth

Rezolute GAAP EPS of -$0.37

Sep 15

We're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Rate

May 06
We're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Rate

Rezolute shares rise on positive topline results from RZ402 eye disease trial

May 04

What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?

Jan 12
What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?

Shareholder Returns

RZLTUS BiotechsUS Market
7D7.8%-0.8%0.9%
1Y-38.9%3.9%-10.9%

Return vs Industry: RZLT underperformed the US Biotechs industry which returned 4.3% over the past year.

Return vs Market: RZLT underperformed the US Market which returned -9.6% over the past year.

Price Volatility

Is RZLT's price volatile compared to industry and market?
RZLT volatility
RZLT Average Weekly Movement12.2%
Biotechs Industry Average Movement12.0%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: RZLT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: RZLT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201042Nevan Elamhttps://www.rezolutebio.com

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company’s lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema.

Rezolute, Inc. Fundamentals Summary

How do Rezolute's earnings and revenue compare to its market cap?
RZLT fundamental statistics
Market CapUS$102.01m
Earnings (TTM)-US$43.05m
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RZLT income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$43.06m
Earnings-US$43.05m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.17
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did RZLT perform over the long term?

See historical performance and comparison